Management of Measles in Children
For children with confirmed measles, management is primarily supportive care, while post-exposure prophylaxis with MMR vaccine (within 72 hours) or immune globulin (within 6 days) should be administered to susceptible contacts to prevent disease spread.
Active Measles Infection Management
When a child presents with active measles infection, treatment focuses on supportive measures as there is no specific antiviral therapy:
- Hydration and nutrition support to manage the common complication of diarrhea
- Antipyretics for fever management
- Monitor for complications including:
- Middle ear infections (otitis media)
- Bronchopneumonia (most common cause of death)
- Encephalitis (occurs in approximately 1 in 1,000 cases)
- Secondary bacterial infections
The case-fatality rate is 1-2 per 1,000 cases in the United States, with infants, young children, and adults at highest risk 1. Pneumonia and acute encephalitis are the leading causes of death, requiring vigilant monitoring and aggressive treatment when they occur.
Special Populations Requiring Intensive Monitoring
- Immunocompromised children (leukemia, lymphoma, HIV): May present without typical rash and can shed virus for weeks after acute illness 1
- Infants under 12 months: Higher complication and mortality risk
- Pregnant adolescents: Increased risk of premature labor, spontaneous abortion, and low birth weight 1
Post-Exposure Prophylaxis (Critical for Contacts)
MMR Vaccine Strategy (Preferred for Most)
For susceptible persons ≥6 months exposed to measles, MMR vaccine within 72 hours of initial exposure is the preferred intervention 1. This approach:
- May prevent infection if given early enough
- Provides long-term immunity even if exposure doesn't result in infection
- Does not increase adverse event risk even if given during presymptomatic period
Key vaccination points:
- Infants vaccinated before 12 months must be revaccinated with two doses of MMR after their first birthday, separated by at least 28 days 1
- Not recommended for immunocompromised persons or pregnant women 1
Immune Globulin Strategy (For High-Risk Contacts)
IG administered within 6 days of exposure can prevent or modify measles 1. Indications include:
- Household contacts at high risk:
- Infants ≤12 months
- Pregnant women
- Immunocompromised persons
- When MMR cannot be given within 72 hours
Dosing:
- Standard dose: 0.25 mL/kg body weight (maximum 15 mL)
- Immunocompromised patients: 0.5 mL/kg (maximum 15 mL)
- Patients on IGIV therapy: ≥100 mg/kg within 3 weeks before exposure is sufficient 1
Critical Timing Caveat
Measles is often not recognized until >72 hours after onset, making IG the more practical option for household contacts not vaccinated within the initial 72-hour window 1.
Post-IG Vaccination Requirement
Any person who receives IG must subsequently receive MMR vaccine no earlier than 5-6 months after IG administration (once ≥12 months old), as passively acquired antibodies interfere with vaccine response 1.
Common Pitfalls to Avoid
- Do not use IG for outbreak control - it is only for individual high-risk contacts 1
- Do not assume infants <6 months are always protected - if the mother has measles, all unvaccinated children in the household need IG regardless of age 1
- Do not give IG to contacts who received measles vaccine after their first birthday unless they are immunocompromised 1